Next Phase Newsletter

An investment firm headquartered in the US focuses on healthcare companies across the seed, venture, and growth stages. The firm typically provides seed and Series A equity financing ranging from $100K to $1M per portfolio company. While the firm often acts as a lead investor, it is also open to participating in syndicated rounds. The firm is open to investment opportunities throughout North America. The firm is actively seeking new investments. 

Current areas of interest include medical devices, diagnostics, digital health, and healthcare-focused software. The firm is also open to reformulated or repurposed drugs, particularly those with reduced development risk. In the medical device category, the firm remains opportunistic across subsectors, with a preference for products that have a prototype and follow the 510(k) regulatory pathway. The firm is indication-agnostic, with interest that includes orphan diseases and the dental field. 

The firm places a strong emphasis on working with experienced management teams and may take a board seat when appropriate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 
This growth-focused investment firm is headquartered in Europe, and was founded by entrepreneurs who previously built and exited a unicorn multinational company. With a renewed mission to drive innovation and growth, the firm targets both early-stage life science ventures and established professional service providers. 

In the early-stage segment, the firm typically invests up to €500K in Series A rounds and makes smaller allocations at the Seed stage. The investment strategy centers on innovative, tech-enabled, and service-oriented companies within the life sciences and healthcare sectors. While the firm is open to early-stage opportunities, it prefers companies with a proven business model and a clear path to scale. 

The firm is eager to partner with strong management teams developing solutions that address unmet needs with a compelling value proposition. Most investments are made as part of a syndicate with institutional venture capital firms, and the firm contributes beyond capital by offering deep sector expertise, an extensive network, and a strong entrepreneurial track record. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An angel syndicate is focused on life science tools and biotech infrastructure. The firm has a concentrated investment strategy targeting U.S.-based companies from the Pre-Seed to Series A stages. The firm’s investor base includes a select group of limited partners, about half of whom are active operators within the life science tools sector. The firm can co-invest but prefers to lead investments, with typical check sizes ranging from $160K to $2M. The firm brings deep domain expertise in life sciences and works closely with founders to build companies, pairing them with strategic capital. The firm is thesis-driven and leverages its extensive operator network, commercial reach, and M&A experience to accelerate company growth and strategy. The firm supports all aspects of business development, from financial modeling and strategic planning to connecting founders with key industry stakeholders within the life sciences ecosystem. 

The firm exclusively targets life science tools, software, biotech infrastructure, and platform technologies that typically include a consumable component. The firm does not invest in therapeutics, diagnostics, digital health, or any business requiring FDA clearance. The firm is open to all development stages and all classes of tools, software, and platform technologies. 

The firm only works with companies whose founders and teams are fully dedicated to their ventures. The firm generally prefers to take a board seat if it leads the investment round and if doing so aligns with the company’s stage of development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

Founded in 2021, an early-stage venture capital firm based in Western Europe invests in multiple verticals. Within life science and healthcare, the firm focuses on medtech and digital health. The sweet point for the firm is pre-seed. Initial investment is typically around €600K, with the potential for follow-on investment of another €600K Euro. The firm is open to opportunities globally with no geographical restrictions. While the firm is open to both leading and co-investing in rounds, the firm would prefer if there is a lead investor in place. 
 
Within life science and healthcare, the firm is focused on medtech and digital health, and is opportunistic in subsectors and indications. Some areas of interest are: surgical devices and cardiovascular diseases. For the stage of development, the firm is open to investing in the preclinical stage, but would prefer companies that have prototypes. 
 
There is no specific requirement for the company’s management team. The firm is interested in working with experienced entrepreneurs. The firm is an active investor and will consider observer seats on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

An investment firm based in the Middle East is a premier investment company with a diverse portfolio spanning multiple asset classes, including real assets and alternative investments. The firm’s vision is to become a leading integrated solutions provider in cell and gene therapy, establishing itself as the first globally trusted partner in precision medicine within the Middle East. The firm focuses on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5–10M. In alignment with national strategic initiatives, the firm aims to act as a catalyst for developing this vital industry and emphasizes the importance of the private sector in supporting emerging, innovative sectors. The firm aspires to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases while contributing to the localization of the biotechnology industry and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1, and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For tech-driven biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve-out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A specialized venture fund with a single limited partner leverages deep expertise in transfusion medicine, cell therapy, and hematology. The firm launched a fund dedicated to early-stage life science investments from Series A to C and has made multiple investments to date. While primarily focused on U.S.-based companies, the firm remains open to global opportunities. 

The firm has four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm is open to therapeutics, diagnostics, and medical devices. Within therapeutics, the firm considers most modalities and prefers programs that are clinical stage or near-clinical stage (IND-ready or submitted). Within diagnostics, the firm prefers technologies at the clinical stage or on the market, with proof of concept demonstrated. Within medical devices, the firm is open to all technologies but is particularly interested in cell therapy-enabling technologies at the clinical stage or on the market, with proof of concept established. With a focus on the need for blood-related and cellular technologies, the firm seeks investments that not only generate financial returns but also align with a humanitarian mission to advance healthcare access and innovation. 

The firm values working with management teams that are fully committed to their projects. The firm prefers teams with a balanced mix of scientific and commercial expertise and takes a collaborative approach as a strategic co-investor, engaging closely with the subject-matter experts within each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology